Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Aug 27

PMID 34440251

Citations 4

Authors

Siddh van Oost

Debora M Meijer

Marieke L Kuijjer

Judith V M G Bovee

Noel F C C de Miranda

Affiliations

Soon will be listed here.

Abstract

Sarcomas comprise a collection of highly heterogeneous malignancies that can be grossly grouped in the categories of sarcomas with simple or complex genomes. Since the outcome for most sarcoma patients has barely improved in the last decades, there is an urgent need for improved therapies. Immunotherapy, and especially T cell checkpoint blockade, has recently been a game-changer in cancer therapy as it produced significant and durable treatment responses in several cancer types. Currently, only a small fraction of sarcoma patients benefit from immunotherapy, supposedly due to a general lack of somatically mutated antigens (neoantigens) and spontaneous T cell immunity in most cancers. However, genomic events resulting from chromosomal instability are frequent in sarcomas with complex genomes and could drive immunity in those tumors. Improving our understanding of the mechanisms that shape the immune landscape of sarcomas will be crucial to overcoming the current challenges of sarcoma immunotherapy. This review focuses on what is currently known about the tumor microenvironment in sarcomas and how this relates to their genomic features. Moreover, we discuss novel therapeutic strategies that leverage the tumor microenvironment to increase the clinical efficacy of immunotherapy, and which could provide new avenues for the treatment of sarcomas.

Citing Articles

Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition.

Waldschmidt J, Haug L, Riedhammer C, Deinzer C, Zimmermann M, Heidemeier A Front Oncol. 2025; 14:1518775.

PMID: 39886672 PMC: 11779609. DOI: 10.3389/fonc.2024.1518775.

Immunological differences between monophasic and biphasic synovial sarcoma with implications for immunotherapy.

Luk S, IJsselsteijn M, Somarakis A, Acem I, de Bruijn I, Szuhai K Cancer Immunol Immunother. 2024; 74(1):31.

PMID: 39708175 PMC: 11663204. DOI: 10.1007/s00262-024-03868-2.

Multimodal profiling of chordoma immunity reveals distinct immune contextures.

van Oost S, Meijer D, Ijsselsteijn M, Roelands J, van den Akker B, van der Breggen R J Immunother Cancer. 2024; 12(1).

PMID: 38272563 PMC: 10824073. DOI: 10.1136/jitc-2023-008138.

The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition.

Anzar I, Malone B, Samarakoon P, Vardaxis I, Simovski B, Fontenelle H Front Immunol. 2023; 14:1226445.

PMID: 37799721 PMC: 10548483. DOI: 10.3389/fimmu.2023.1226445.

Editorial: Unravelling the sarcoma microenvironment: Impact of the genomic landscape on molecular signaling, immunosuppression, and treatment resistance.

Dickerson E, Chen E, Kim J Front Oncol. 2023; 13:1180954.

PMID: 37035184 PMC: 10080149. DOI: 10.3389/fonc.2023.1180954.

References

Lhuillier C, Rudqvist N, Elemento O, Formenti S, Demaria S . Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Med. 2019; 11(1):40. PMC: 6587285. DOI: 10.1186/s13073-019-0653-7. View

Melief C, van Hall T, Arens R, Ossendorp F, van der Burg S . Therapeutic cancer vaccines. J Clin Invest. 2015; 125(9):3401-12. PMC: 4588240. DOI: 10.1172/JCI80009. View

Chen H, Song Y, Deng C, Xu Y, Xu H, Zhu X . Comprehensive analysis of immune infiltration and gene expression for predicting survival in patients with sarcomas. Aging (Albany NY). 2020; 13(2):2168-2183. PMC: 7880383. DOI: 10.18632/aging.202229. View

Sundara Y, Kostine M, Cleven A, Bovee J, Schilham M, Cleton-Jansen A . Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother. 2016; 66(1):119-128. PMC: 5222929. DOI: 10.1007/s00262-016-1925-3. View

Sahin U, Tureci O . Personalized vaccines for cancer immunotherapy. Science. 2018; 359(6382):1355-1360. DOI: 10.1126/science.aar7112. View

Tseng W, Malu S, Zhang M, Chen J, Sim G, Wei W . Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma. 2015; 2015:547460. PMC: 4326351. DOI: 10.1155/2015/547460. View

Miwa S, Nishida H, Tanzawa Y, Takeuchi A, Hayashi K, Yamamoto N . Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma. Cancer. 2017; 123(9):1576-1584. DOI: 10.1002/cncr.30606. View

Luk S, van der Steen D, Hagedoorn R, Jordanova E, Schilham M, Bovee J . PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy. Oncoimmunology. 2018; 7(12):e1507600. PMC: 6279314. DOI: 10.1080/2162402X.2018.1507600. View

Miao D, Margolis C, Gao W, Voss M, Li W, Martini D . Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018; 359(6377):801-806. PMC: 6035749. DOI: 10.1126/science.aan5951. View

10.

Oike N, Kawashima H, Ogose A, Hotta T, Hatano H, Ariizumi T . Prognostic impact of the tumor immune microenvironment in synovial sarcoma. Cancer Sci. 2018; 109(10):3043-3054. PMC: 6172059. DOI: 10.1111/cas.13769. View

11.

Thanindratarn P, Dean D, Nelson S, Hornicek F, Duan Z . Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications. Cancer Treat Rev. 2019; 82:101934. DOI: 10.1016/j.ctrv.2019.101934. View

12.

McGrail D, Federico L, Li Y, Dai H, Lu Y, Mills G . Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun. 2018; 9(1):1317. PMC: 5882811. DOI: 10.1038/s41467-018-03730-x. View

13.

Sautes-Fridman C, Petitprez F, Calderaro J, Fridman W . Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019; 19(6):307-325. DOI: 10.1038/s41568-019-0144-6. View

14.

Tawbi H, Burgess M, Bolejack V, Van Tine B, Schuetze S, Hu J . Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017; 18(11):1493-1501. PMC: 7939029. DOI: 10.1016/S1470-2045(17)30624-1. View

15.

Kawaguchi S, Wada T, Ida K, Sato Y, Nagoya S, Tsukahara T . Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med. 2005; 3(1):1. PMC: 545052. DOI: 10.1186/1479-5876-3-1. View

16.

Wilky B, Trucco M, Subhawong T, Florou V, Park W, Kwon D . Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2019; 20(6):837-848. DOI: 10.1016/S1470-2045(19)30153-6. View

17.

Kawaguchi S, Tsukahara T, Ida K, Kimura S, Murase M, Kano M . SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group. Cancer Sci. 2012; 103(9):1625-30. PMC: 7659233. DOI: 10.1111/j.1349-7006.2012.02370.x. View

18.

Yang W, Lee K, Srivastava R, Kuo F, Krishna C, Chowell D . Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med. 2019; 25(5):767-775. PMC: 6558662. DOI: 10.1038/s41591-019-0434-2. View

19.

van den Bulk J, de Miranda N, Ten Dijke P . Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression. Clin Sci (Lond). 2021; 135(1):35-52. PMC: 7796313. DOI: 10.1042/CS20201236. View

20.

Ogose A, Kawashima H, Hotta T, Ariizumi T, Yamagishi T, Oike N . Frequent expression of human leukocyte antigen class I and the status of intratumoral immune cells in alveolar soft part sarcoma. Oncol Lett. 2017; 13(4):2169-2176. PMC: 5403429. DOI: 10.3892/ol.2017.5696. View